Anti-interleukin-1 alpha antibody MABp1 improves outcomes significantly over placebo
MABp1 improves symptoms, reduces inflammation and increases clinical response rate by 76%, with a 3x longer survival time for responders. Excellent safety and tolerability were also observed.